Jigarkumar Parikh, MD
Hematology & Oncology · Augusta, GANPI 1073775722
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $178,270 of the $266,620 with a category attached, or 66.9%. 54 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 28.5% of the total. Reporting peaked in 2023 at $71,340 and has fallen 66.9% since, to $23,583 in 2025. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 677 payments — averaging $393.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$76K
- Exelixis Inc.$68K
- Bayer$44K
- Pfizer$16K
- Astellas Pharma US Inc$16K
- Seagen Inc.$14K
- plus $33K from 48 others
Across 190 payments — averaging $9693.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- EMD Serono, Inc.$278K
- AstraZeneca$200K
- E.r. Squibb & Sons, L.L.C.$94K
- Seagen Inc.$54K
- Astrazeneca UK Limited$38K
What the payments were for
- Consulting fees$47,78018%
- Speaking & faculty fees$178,27067%
- Travel & lodging$28,48811%
- Food & beverage$11,3044%
- Education$7790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$266,620 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 57 | $1,138,677 |
| NubeqaDarolutamide | 90 | $1,079,354 |
| XtandiEnzalutamide | 85 | $849,847 |
| PomalystPomalidomide | 33 | $709,560 |
| LenvimaLenvatinib Mesylate | 19 | $445,813 |
| RevlimidLenalidomide | 31 | $432,250 |
| ErleadaApalutamide | 34 | $404,744 |
| TibsovoIvosidenib | 13 | $381,181 |
| ImbruvicaIbrutinib | 44 | $315,425 |
| TalzennaTalazoparib Tosylate | 17 | $264,341 |
| TagrissoOsimertinib Mesylate | 16 | $264,164 |
| KisqaliRibociclib Succinate | 16 | $213,644 |
| Abiraterone Acetate | 97 | $180,131 |
| EliquisApixaban | 105 | $68,132 |
| BrukinsaZanubrutinib | 11 | $45,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $68,447 | $1,138,67757 claims |
| BayerNubeqa | $44,439 | $1,079,35490 claims |
| Astellas Pharma US IncXtandi | $15,622 | $849,84785 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $75,872 | $709,56033 claims |
| Eisai Inc.Lenvima | $285 | $445,81319 claims |
| Bristol Myers SquibbRevlimid | $3,608 | $432,25031 claims |
| Johnson & JohnsonErleada | $591 | $404,74434 claims |
| PfizerTalzenna, Eliquis, Nivestym | $16,004 | $347,419139 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $43 | $315,42544 claims |
| AstraZenecaTagrisso | $11,270 | $264,16416 claims |
| NovartisKisqali | $754 | $213,64416 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,010 | $180,13197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Augusta
- Abdullah KutlarAugusta$196K
- Vamsi KotaAugusta$91K
- Girindra RavalAugusta$88K
- Brent LimbaughAugusta$72K
- Amany KeruakousAugusta$36K
- Eugene LongAugusta$34K
- David SquiresAugusta$33K
- Miriam AtkinsAugusta$28K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.